nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—lung cancer	0.239	1	CbGaD
Valsartan—SLCO1B3—Paclitaxel—lung cancer	0.0914	0.183	CbGbCtD
Valsartan—SLCO1B3—Docetaxel—lung cancer	0.0661	0.132	CbGbCtD
Valsartan—ALB—Gefitinib—lung cancer	0.0539	0.108	CbGbCtD
Valsartan—SLCO1B1—Irinotecan—lung cancer	0.0525	0.105	CbGbCtD
Valsartan—SLCO1B3—Methotrexate—lung cancer	0.0477	0.0953	CbGbCtD
Valsartan—ALB—Erlotinib—lung cancer	0.0318	0.0636	CbGbCtD
Valsartan—CYP2C9—Gefitinib—lung cancer	0.029	0.058	CbGbCtD
Valsartan—ALB—Irinotecan—lung cancer	0.0288	0.0574	CbGbCtD
Valsartan—CYP2C9—Teniposide—lung cancer	0.0281	0.0562	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—lung cancer	0.0278	0.0555	CbGbCtD
Valsartan—CYP2C9—Paclitaxel—lung cancer	0.0157	0.0314	CbGbCtD
Valsartan—ALB—Methotrexate—lung cancer	0.0152	0.0304	CbGbCtD
Valsartan—CYP2C9—Cisplatin—lung cancer	0.0126	0.0252	CbGbCtD
Valsartan—Irbesartan—JUN—lung cancer	0.00207	0.584	CrCbGaD
Valsartan—Losartan—UGT1A1—lung cancer	0.000799	0.226	CrCbGaD
Valsartan—Candesartan—ABCB1—lung cancer	0.00029	0.0819	CrCbGaD
Valsartan—Losartan—ALB—lung cancer	0.000196	0.0553	CrCbGaD
Valsartan—Losartan—ABCB1—lung cancer	0.000187	0.0528	CrCbGaD
Valsartan—Photosensitivity reaction—Methotrexate—lung cancer	0.000127	0.000697	CcSEcCtD
Valsartan—Thrombocytopenia—Paclitaxel—lung cancer	0.000127	0.000696	CcSEcCtD
Valsartan—Anorexia—Etoposide—lung cancer	0.000126	0.000691	CcSEcCtD
Valsartan—Skin disorder—Paclitaxel—lung cancer	0.000126	0.00069	CcSEcCtD
Valsartan—Abdominal pain—Irinotecan—lung cancer	0.000126	0.000689	CcSEcCtD
Valsartan—Decreased appetite—Cisplatin—lung cancer	0.000126	0.000688	CcSEcCtD
Valsartan—Gastrointestinal disorder—Cisplatin—lung cancer	0.000125	0.000683	CcSEcCtD
Valsartan—Infestation NOS—Methotrexate—lung cancer	0.000124	0.000681	CcSEcCtD
Valsartan—Infestation—Methotrexate—lung cancer	0.000124	0.000681	CcSEcCtD
Valsartan—Anorexia—Paclitaxel—lung cancer	0.000124	0.000677	CcSEcCtD
Valsartan—Hypotension—Etoposide—lung cancer	0.000124	0.000677	CcSEcCtD
Valsartan—Muscular weakness—Doxorubicin—lung cancer	0.000123	0.000674	CcSEcCtD
Valsartan—Vomiting—Vinorelbine—lung cancer	0.000123	0.000672	CcSEcCtD
Valsartan—Renal failure—Methotrexate—lung cancer	0.000122	0.000669	CcSEcCtD
Valsartan—Rash—Vinorelbine—lung cancer	0.000122	0.000666	CcSEcCtD
Valsartan—Dermatitis—Vinorelbine—lung cancer	0.000122	0.000665	CcSEcCtD
Valsartan—Hypotension—Paclitaxel—lung cancer	0.000121	0.000664	CcSEcCtD
Valsartan—Headache—Vinorelbine—lung cancer	0.000121	0.000662	CcSEcCtD
Valsartan—Syncope—Docetaxel—lung cancer	0.000121	0.000662	CcSEcCtD
Valsartan—Palpitations—Docetaxel—lung cancer	0.000119	0.000652	CcSEcCtD
Valsartan—Paraesthesia—Etoposide—lung cancer	0.000119	0.000651	CcSEcCtD
Valsartan—Loss of consciousness—Docetaxel—lung cancer	0.000118	0.000649	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000118	0.000647	CcSEcCtD
Valsartan—Dyspnoea—Etoposide—lung cancer	0.000118	0.000646	CcSEcCtD
Valsartan—Somnolence—Etoposide—lung cancer	0.000118	0.000644	CcSEcCtD
Valsartan—Cough—Docetaxel—lung cancer	0.000118	0.000644	CcSEcCtD
Valsartan—Insomnia—Paclitaxel—lung cancer	0.000117	0.000643	CcSEcCtD
Valsartan—Epistaxis—Methotrexate—lung cancer	0.000117	0.000642	CcSEcCtD
Valsartan—Hypersensitivity—Irinotecan—lung cancer	0.000117	0.000642	CcSEcCtD
Valsartan—Paraesthesia—Paclitaxel—lung cancer	0.000117	0.000638	CcSEcCtD
Valsartan—Bronchitis—Doxorubicin—lung cancer	0.000116	0.000636	CcSEcCtD
Valsartan—Dyspnoea—Paclitaxel—lung cancer	0.000116	0.000633	CcSEcCtD
Valsartan—Somnolence—Paclitaxel—lung cancer	0.000115	0.000632	CcSEcCtD
Valsartan—Decreased appetite—Etoposide—lung cancer	0.000115	0.00063	CcSEcCtD
Valsartan—Myalgia—Docetaxel—lung cancer	0.000115	0.000628	CcSEcCtD
Valsartan—Chest pain—Docetaxel—lung cancer	0.000115	0.000628	CcSEcCtD
Valsartan—Arthralgia—Docetaxel—lung cancer	0.000115	0.000628	CcSEcCtD
Valsartan—Nausea—Vinorelbine—lung cancer	0.000115	0.000627	CcSEcCtD
Valsartan—Gastrointestinal disorder—Etoposide—lung cancer	0.000114	0.000626	CcSEcCtD
Valsartan—Dyspepsia—Paclitaxel—lung cancer	0.000114	0.000625	CcSEcCtD
Valsartan—Asthenia—Irinotecan—lung cancer	0.000114	0.000625	CcSEcCtD
Valsartan—Fatigue—Etoposide—lung cancer	0.000114	0.000625	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000114	0.000624	CcSEcCtD
Valsartan—Constipation—Etoposide—lung cancer	0.000113	0.00062	CcSEcCtD
Valsartan—Neutropenia—Doxorubicin—lung cancer	0.000113	0.000618	CcSEcCtD
Valsartan—Decreased appetite—Paclitaxel—lung cancer	0.000113	0.000618	CcSEcCtD
Valsartan—Dry mouth—Docetaxel—lung cancer	0.000112	0.000614	CcSEcCtD
Valsartan—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000112	0.000614	CcSEcCtD
Valsartan—Haemoglobin—Methotrexate—lung cancer	0.000112	0.000614	CcSEcCtD
Valsartan—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000112	0.000613	CcSEcCtD
Valsartan—Fatigue—Paclitaxel—lung cancer	0.000112	0.000613	CcSEcCtD
Valsartan—Haemorrhage—Methotrexate—lung cancer	0.000112	0.000611	CcSEcCtD
Valsartan—Hepatitis—Methotrexate—lung cancer	0.000112	0.000611	CcSEcCtD
Valsartan—Asthenia—Gemcitabine—lung cancer	0.000111	0.000609	CcSEcCtD
Valsartan—Constipation—Paclitaxel—lung cancer	0.000111	0.000608	CcSEcCtD
Valsartan—Pharyngitis—Methotrexate—lung cancer	0.000111	0.000606	CcSEcCtD
Valsartan—Urinary tract disorder—Methotrexate—lung cancer	0.00011	0.000603	CcSEcCtD
Valsartan—Photosensitivity reaction—Doxorubicin—lung cancer	0.00011	0.000603	CcSEcCtD
Valsartan—Anaphylactic shock—Docetaxel—lung cancer	0.00011	0.000602	CcSEcCtD
Valsartan—Oedema—Docetaxel—lung cancer	0.00011	0.000602	CcSEcCtD
Valsartan—Pruritus—Gemcitabine—lung cancer	0.00011	0.0006	CcSEcCtD
Valsartan—Urethral disorder—Methotrexate—lung cancer	0.000109	0.000599	CcSEcCtD
Valsartan—Infection—Docetaxel—lung cancer	0.000109	0.000598	CcSEcCtD
Valsartan—Diarrhoea—Irinotecan—lung cancer	0.000109	0.000596	CcSEcCtD
Valsartan—Gastrointestinal pain—Etoposide—lung cancer	0.000108	0.000593	CcSEcCtD
Valsartan—Shock—Docetaxel—lung cancer	0.000108	0.000593	CcSEcCtD
Valsartan—Nervous system disorder—Docetaxel—lung cancer	0.000108	0.000591	CcSEcCtD
Valsartan—Thrombocytopenia—Docetaxel—lung cancer	0.000108	0.00059	CcSEcCtD
Valsartan—Infestation—Doxorubicin—lung cancer	0.000108	0.000589	CcSEcCtD
Valsartan—Infestation NOS—Doxorubicin—lung cancer	0.000108	0.000589	CcSEcCtD
Valsartan—Skin disorder—Docetaxel—lung cancer	0.000107	0.000585	CcSEcCtD
Valsartan—Hypersensitivity—Cisplatin—lung cancer	0.000106	0.000583	CcSEcCtD
Valsartan—Gastrointestinal pain—Paclitaxel—lung cancer	0.000106	0.000581	CcSEcCtD
Valsartan—Diarrhoea—Gemcitabine—lung cancer	0.000106	0.000581	CcSEcCtD
Valsartan—Renal failure—Doxorubicin—lung cancer	0.000106	0.000579	CcSEcCtD
Valsartan—Dizziness—Irinotecan—lung cancer	0.000105	0.000576	CcSEcCtD
Valsartan—Urticaria—Etoposide—lung cancer	0.000105	0.000576	CcSEcCtD
Valsartan—Anorexia—Docetaxel—lung cancer	0.000105	0.000574	CcSEcCtD
Valsartan—Abdominal pain—Etoposide—lung cancer	0.000105	0.000573	CcSEcCtD
Valsartan—Asthenia—Cisplatin—lung cancer	0.000104	0.000568	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—lung cancer	0.000104	0.000567	CcSEcCtD
Valsartan—Urticaria—Paclitaxel—lung cancer	0.000103	0.000564	CcSEcCtD
Valsartan—Hypotension—Docetaxel—lung cancer	0.000103	0.000563	CcSEcCtD
Valsartan—Abdominal pain—Paclitaxel—lung cancer	0.000103	0.000562	CcSEcCtD
Valsartan—Epistaxis—Doxorubicin—lung cancer	0.000102	0.000556	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—lung cancer	0.000101	0.000554	CcSEcCtD
Valsartan—Vomiting—Irinotecan—lung cancer	0.000101	0.000554	CcSEcCtD
Valsartan—Sinusitis—Doxorubicin—lung cancer	0.000101	0.000553	CcSEcCtD
Valsartan—Immune system disorder—Methotrexate—lung cancer	0.000101	0.000552	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—lung cancer	0.000101	0.000551	CcSEcCtD
Valsartan—Rash—Irinotecan—lung cancer	0.0001	0.000549	CcSEcCtD
Valsartan—Dermatitis—Irinotecan—lung cancer	0.0001	0.000549	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Docetaxel—lung cancer	0.0001	0.000549	CcSEcCtD
Valsartan—Headache—Irinotecan—lung cancer	9.97e-05	0.000546	CcSEcCtD
Valsartan—Insomnia—Docetaxel—lung cancer	9.95e-05	0.000545	CcSEcCtD
Valsartan—Diarrhoea—Cisplatin—lung cancer	9.89e-05	0.000541	CcSEcCtD
Valsartan—Paraesthesia—Docetaxel—lung cancer	9.88e-05	0.000541	CcSEcCtD
Valsartan—Alopecia—Methotrexate—lung cancer	9.86e-05	0.00054	CcSEcCtD
Valsartan—Vomiting—Gemcitabine—lung cancer	9.86e-05	0.00054	CcSEcCtD
Valsartan—Dyspnoea—Docetaxel—lung cancer	9.81e-05	0.000537	CcSEcCtD
Valsartan—Somnolence—Docetaxel—lung cancer	9.78e-05	0.000535	CcSEcCtD
Valsartan—Mental disorder—Methotrexate—lung cancer	9.78e-05	0.000535	CcSEcCtD
Valsartan—Rash—Gemcitabine—lung cancer	9.77e-05	0.000535	CcSEcCtD
Valsartan—Dermatitis—Gemcitabine—lung cancer	9.77e-05	0.000535	CcSEcCtD
Valsartan—Hypersensitivity—Etoposide—lung cancer	9.75e-05	0.000534	CcSEcCtD
Valsartan—Malnutrition—Methotrexate—lung cancer	9.72e-05	0.000532	CcSEcCtD
Valsartan—Haemoglobin—Doxorubicin—lung cancer	9.71e-05	0.000532	CcSEcCtD
Valsartan—Headache—Gemcitabine—lung cancer	9.71e-05	0.000532	CcSEcCtD
Valsartan—Rhinitis—Doxorubicin—lung cancer	9.69e-05	0.00053	CcSEcCtD
Valsartan—Dyspepsia—Docetaxel—lung cancer	9.68e-05	0.00053	CcSEcCtD
Valsartan—Hepatitis—Doxorubicin—lung cancer	9.66e-05	0.000529	CcSEcCtD
Valsartan—Haemorrhage—Doxorubicin—lung cancer	9.66e-05	0.000529	CcSEcCtD
Valsartan—Pharyngitis—Doxorubicin—lung cancer	9.59e-05	0.000525	CcSEcCtD
Valsartan—Decreased appetite—Docetaxel—lung cancer	9.56e-05	0.000524	CcSEcCtD
Valsartan—Hypersensitivity—Paclitaxel—lung cancer	9.56e-05	0.000523	CcSEcCtD
Valsartan—Urinary tract disorder—Doxorubicin—lung cancer	9.54e-05	0.000522	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—lung cancer	9.51e-05	0.000521	CcSEcCtD
Valsartan—Gastrointestinal disorder—Docetaxel—lung cancer	9.5e-05	0.00052	CcSEcCtD
Valsartan—Asthenia—Etoposide—lung cancer	9.5e-05	0.00052	CcSEcCtD
Valsartan—Connective tissue disorder—Doxorubicin—lung cancer	9.5e-05	0.00052	CcSEcCtD
Valsartan—Fatigue—Docetaxel—lung cancer	9.49e-05	0.000519	CcSEcCtD
Valsartan—Urethral disorder—Doxorubicin—lung cancer	9.47e-05	0.000519	CcSEcCtD
Valsartan—Nausea—Irinotecan—lung cancer	9.45e-05	0.000517	CcSEcCtD
Valsartan—Constipation—Docetaxel—lung cancer	9.41e-05	0.000515	CcSEcCtD
Valsartan—Back pain—Methotrexate—lung cancer	9.4e-05	0.000514	CcSEcCtD
Valsartan—Pruritus—Etoposide—lung cancer	9.37e-05	0.000513	CcSEcCtD
Valsartan—Asthenia—Paclitaxel—lung cancer	9.31e-05	0.00051	CcSEcCtD
Valsartan—Nausea—Gemcitabine—lung cancer	9.21e-05	0.000504	CcSEcCtD
Valsartan—Vomiting—Cisplatin—lung cancer	9.19e-05	0.000503	CcSEcCtD
Valsartan—Pruritus—Paclitaxel—lung cancer	9.18e-05	0.000503	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—lung cancer	9.16e-05	0.000501	CcSEcCtD
Valsartan—Rash—Cisplatin—lung cancer	9.11e-05	0.000499	CcSEcCtD
Valsartan—Dermatitis—Cisplatin—lung cancer	9.1e-05	0.000498	CcSEcCtD
Valsartan—Diarrhoea—Etoposide—lung cancer	9.06e-05	0.000496	CcSEcCtD
Valsartan—Gastrointestinal pain—Docetaxel—lung cancer	9e-05	0.000492	CcSEcCtD
Valsartan—Cardiac disorder—Doxorubicin—lung cancer	8.97e-05	0.000491	CcSEcCtD
Valsartan—Diarrhoea—Paclitaxel—lung cancer	8.88e-05	0.000486	CcSEcCtD
Valsartan—Angiopathy—Doxorubicin—lung cancer	8.77e-05	0.00048	CcSEcCtD
Valsartan—Dizziness—Etoposide—lung cancer	8.75e-05	0.000479	CcSEcCtD
Valsartan—Immune system disorder—Doxorubicin—lung cancer	8.73e-05	0.000478	CcSEcCtD
Valsartan—Vertigo—Methotrexate—lung cancer	8.73e-05	0.000478	CcSEcCtD
Valsartan—Mediastinal disorder—Doxorubicin—lung cancer	8.71e-05	0.000477	CcSEcCtD
Valsartan—Abdominal pain—Docetaxel—lung cancer	8.7e-05	0.000476	CcSEcCtD
Valsartan—Dizziness—Paclitaxel—lung cancer	8.58e-05	0.00047	CcSEcCtD
Valsartan—Nausea—Cisplatin—lung cancer	8.58e-05	0.00047	CcSEcCtD
Valsartan—Alopecia—Doxorubicin—lung cancer	8.54e-05	0.000467	CcSEcCtD
Valsartan—Cough—Methotrexate—lung cancer	8.48e-05	0.000464	CcSEcCtD
Valsartan—Mental disorder—Doxorubicin—lung cancer	8.47e-05	0.000463	CcSEcCtD
Valsartan—Vomiting—Etoposide—lung cancer	8.42e-05	0.000461	CcSEcCtD
Valsartan—Malnutrition—Doxorubicin—lung cancer	8.41e-05	0.000461	CcSEcCtD
Valsartan—Rash—Etoposide—lung cancer	8.35e-05	0.000457	CcSEcCtD
Valsartan—Dermatitis—Etoposide—lung cancer	8.34e-05	0.000456	CcSEcCtD
Valsartan—Headache—Etoposide—lung cancer	8.29e-05	0.000454	CcSEcCtD
Valsartan—Flatulence—Doxorubicin—lung cancer	8.29e-05	0.000454	CcSEcCtD
Valsartan—Chest pain—Methotrexate—lung cancer	8.27e-05	0.000453	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—lung cancer	8.27e-05	0.000453	CcSEcCtD
Valsartan—Myalgia—Methotrexate—lung cancer	8.27e-05	0.000453	CcSEcCtD
Valsartan—Vomiting—Paclitaxel—lung cancer	8.25e-05	0.000452	CcSEcCtD
Valsartan—Dysgeusia—Doxorubicin—lung cancer	8.24e-05	0.000451	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	8.21e-05	0.00045	CcSEcCtD
Valsartan—Rash—Paclitaxel—lung cancer	8.18e-05	0.000448	CcSEcCtD
Valsartan—Dermatitis—Paclitaxel—lung cancer	8.18e-05	0.000448	CcSEcCtD
Valsartan—Back pain—Doxorubicin—lung cancer	8.14e-05	0.000445	CcSEcCtD
Valsartan—Headache—Paclitaxel—lung cancer	8.13e-05	0.000445	CcSEcCtD
Valsartan—Hypersensitivity—Docetaxel—lung cancer	8.11e-05	0.000444	CcSEcCtD
Valsartan—Muscle spasms—Doxorubicin—lung cancer	8.09e-05	0.000443	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—lung cancer	7.93e-05	0.000434	CcSEcCtD
Valsartan—Vision blurred—Doxorubicin—lung cancer	7.93e-05	0.000434	CcSEcCtD
Valsartan—Asthenia—Docetaxel—lung cancer	7.89e-05	0.000432	CcSEcCtD
Valsartan—Infection—Methotrexate—lung cancer	7.88e-05	0.000431	CcSEcCtD
Valsartan—Nausea—Etoposide—lung cancer	7.86e-05	0.00043	CcSEcCtD
Valsartan—Pruritus—Docetaxel—lung cancer	7.78e-05	0.000426	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—lung cancer	7.78e-05	0.000426	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—lung cancer	7.76e-05	0.000425	CcSEcCtD
Valsartan—Nausea—Paclitaxel—lung cancer	7.71e-05	0.000422	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—lung cancer	7.7e-05	0.000422	CcSEcCtD
Valsartan—Vertigo—Doxorubicin—lung cancer	7.56e-05	0.000414	CcSEcCtD
Valsartan—Anorexia—Methotrexate—lung cancer	7.56e-05	0.000414	CcSEcCtD
Valsartan—Syncope—Doxorubicin—lung cancer	7.54e-05	0.000413	CcSEcCtD
Valsartan—Diarrhoea—Docetaxel—lung cancer	7.53e-05	0.000412	CcSEcCtD
Valsartan—Palpitations—Doxorubicin—lung cancer	7.43e-05	0.000407	CcSEcCtD
Valsartan—Hypotension—Methotrexate—lung cancer	7.41e-05	0.000406	CcSEcCtD
Valsartan—Loss of consciousness—Doxorubicin—lung cancer	7.39e-05	0.000405	CcSEcCtD
Valsartan—Cough—Doxorubicin—lung cancer	7.34e-05	0.000402	CcSEcCtD
Valsartan—Dizziness—Docetaxel—lung cancer	7.28e-05	0.000398	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methotrexate—lung cancer	7.22e-05	0.000395	CcSEcCtD
Valsartan—Insomnia—Methotrexate—lung cancer	7.17e-05	0.000393	CcSEcCtD
Valsartan—Chest pain—Doxorubicin—lung cancer	7.16e-05	0.000392	CcSEcCtD
Valsartan—Arthralgia—Doxorubicin—lung cancer	7.16e-05	0.000392	CcSEcCtD
Valsartan—Myalgia—Doxorubicin—lung cancer	7.16e-05	0.000392	CcSEcCtD
Valsartan—Anxiety—Doxorubicin—lung cancer	7.14e-05	0.000391	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—lung cancer	7.12e-05	0.00039	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	7.11e-05	0.000389	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—lung cancer	7.07e-05	0.000387	CcSEcCtD
Valsartan—Somnolence—Methotrexate—lung cancer	7.05e-05	0.000386	CcSEcCtD
Valsartan—Dry mouth—Doxorubicin—lung cancer	7e-05	0.000383	CcSEcCtD
Valsartan—Vomiting—Docetaxel—lung cancer	7e-05	0.000383	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—lung cancer	6.98e-05	0.000382	CcSEcCtD
Valsartan—Rash—Docetaxel—lung cancer	6.94e-05	0.00038	CcSEcCtD
Valsartan—Dermatitis—Docetaxel—lung cancer	6.93e-05	0.000379	CcSEcCtD
Valsartan—Decreased appetite—Methotrexate—lung cancer	6.89e-05	0.000377	CcSEcCtD
Valsartan—Headache—Docetaxel—lung cancer	6.89e-05	0.000377	CcSEcCtD
Valsartan—Oedema—Doxorubicin—lung cancer	6.87e-05	0.000376	CcSEcCtD
Valsartan—Anaphylactic shock—Doxorubicin—lung cancer	6.87e-05	0.000376	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—lung cancer	6.85e-05	0.000375	CcSEcCtD
Valsartan—Fatigue—Methotrexate—lung cancer	6.84e-05	0.000374	CcSEcCtD
Valsartan—Infection—Doxorubicin—lung cancer	6.82e-05	0.000373	CcSEcCtD
Valsartan—Shock—Doxorubicin—lung cancer	6.76e-05	0.00037	CcSEcCtD
Valsartan—Nervous system disorder—Doxorubicin—lung cancer	6.73e-05	0.000369	CcSEcCtD
Valsartan—Thrombocytopenia—Doxorubicin—lung cancer	6.72e-05	0.000368	CcSEcCtD
Valsartan—Skin disorder—Doxorubicin—lung cancer	6.67e-05	0.000365	CcSEcCtD
Valsartan—Anorexia—Doxorubicin—lung cancer	6.54e-05	0.000358	CcSEcCtD
Valsartan—Nausea—Docetaxel—lung cancer	6.53e-05	0.000358	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—lung cancer	6.48e-05	0.000355	CcSEcCtD
Valsartan—Hypotension—Doxorubicin—lung cancer	6.42e-05	0.000351	CcSEcCtD
Valsartan—Urticaria—Methotrexate—lung cancer	6.3e-05	0.000345	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—lung cancer	6.27e-05	0.000343	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Doxorubicin—lung cancer	6.26e-05	0.000342	CcSEcCtD
Valsartan—Insomnia—Doxorubicin—lung cancer	6.21e-05	0.00034	CcSEcCtD
Valsartan—Paraesthesia—Doxorubicin—lung cancer	6.17e-05	0.000337	CcSEcCtD
Valsartan—Dyspnoea—Doxorubicin—lung cancer	6.12e-05	0.000335	CcSEcCtD
Valsartan—Somnolence—Doxorubicin—lung cancer	6.1e-05	0.000334	CcSEcCtD
Valsartan—Dyspepsia—Doxorubicin—lung cancer	6.04e-05	0.000331	CcSEcCtD
Valsartan—Decreased appetite—Doxorubicin—lung cancer	5.97e-05	0.000327	CcSEcCtD
Valsartan—Gastrointestinal disorder—Doxorubicin—lung cancer	5.93e-05	0.000324	CcSEcCtD
Valsartan—Fatigue—Doxorubicin—lung cancer	5.92e-05	0.000324	CcSEcCtD
Valsartan—Constipation—Doxorubicin—lung cancer	5.87e-05	0.000321	CcSEcCtD
Valsartan—Hypersensitivity—Methotrexate—lung cancer	5.84e-05	0.00032	CcSEcCtD
Valsartan—Asthenia—Methotrexate—lung cancer	5.69e-05	0.000311	CcSEcCtD
Valsartan—Gastrointestinal pain—Doxorubicin—lung cancer	5.61e-05	0.000307	CcSEcCtD
Valsartan—Pruritus—Methotrexate—lung cancer	5.61e-05	0.000307	CcSEcCtD
Valsartan—Urticaria—Doxorubicin—lung cancer	5.45e-05	0.000299	CcSEcCtD
Valsartan—Abdominal pain—Doxorubicin—lung cancer	5.43e-05	0.000297	CcSEcCtD
Valsartan—Diarrhoea—Methotrexate—lung cancer	5.43e-05	0.000297	CcSEcCtD
Valsartan—Dizziness—Methotrexate—lung cancer	5.24e-05	0.000287	CcSEcCtD
Valsartan—Hypersensitivity—Doxorubicin—lung cancer	5.06e-05	0.000277	CcSEcCtD
Valsartan—Vomiting—Methotrexate—lung cancer	5.04e-05	0.000276	CcSEcCtD
Valsartan—Rash—Methotrexate—lung cancer	5e-05	0.000274	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—lung cancer	5e-05	0.000273	CcSEcCtD
Valsartan—Headache—Methotrexate—lung cancer	4.97e-05	0.000272	CcSEcCtD
Valsartan—Asthenia—Doxorubicin—lung cancer	4.93e-05	0.00027	CcSEcCtD
Valsartan—Pruritus—Doxorubicin—lung cancer	4.86e-05	0.000266	CcSEcCtD
Valsartan—Nausea—Methotrexate—lung cancer	4.71e-05	0.000258	CcSEcCtD
Valsartan—Diarrhoea—Doxorubicin—lung cancer	4.7e-05	0.000257	CcSEcCtD
Valsartan—Dizziness—Doxorubicin—lung cancer	4.54e-05	0.000249	CcSEcCtD
Valsartan—Vomiting—Doxorubicin—lung cancer	4.37e-05	0.000239	CcSEcCtD
Valsartan—Rash—Doxorubicin—lung cancer	4.33e-05	0.000237	CcSEcCtD
Valsartan—Dermatitis—Doxorubicin—lung cancer	4.33e-05	0.000237	CcSEcCtD
Valsartan—Headache—Doxorubicin—lung cancer	4.3e-05	0.000235	CcSEcCtD
Valsartan—Nausea—Doxorubicin—lung cancer	4.08e-05	0.000223	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—IGF1R—lung cancer	2.2e-05	0.000299	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL8—lung cancer	2.19e-05	0.000297	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—lung cancer	2.18e-05	0.000296	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HES1—lung cancer	2.16e-05	0.000293	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2—lung cancer	2.16e-05	0.000292	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP1A1—lung cancer	2.13e-05	0.000289	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—RAF1—lung cancer	2.12e-05	0.000288	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ERCC2—lung cancer	2.11e-05	0.000286	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2—lung cancer	2.1e-05	0.000284	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM2—lung cancer	2.08e-05	0.000282	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CNDP2—lung cancer	2.08e-05	0.000282	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—lung cancer	2.08e-05	0.000281	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CB—lung cancer	2.07e-05	0.000281	CbGpPWpGaD
Valsartan—ALB—Metabolism—RRM1—lung cancer	2.05e-05	0.000278	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTA3—lung cancer	2.05e-05	0.000278	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTMR3—lung cancer	2.03e-05	0.000275	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL8—lung cancer	1.99e-05	0.00027	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP2E1—lung cancer	1.99e-05	0.00027	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ERBB3—lung cancer	1.98e-05	0.000268	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PGAM1—lung cancer	1.98e-05	0.000268	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NQO1—lung cancer	1.97e-05	0.000267	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—AVP—lung cancer	1.96e-05	0.000265	CbGpPWpGaD
Valsartan—ALB—Metabolism—B4GALT5—lung cancer	1.93e-05	0.000262	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.93e-05	0.000261	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.91e-05	0.000259	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2—lung cancer	1.9e-05	0.000258	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TERT—lung cancer	1.9e-05	0.000257	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ABCB1—lung cancer	1.9e-05	0.000257	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2A7—lung cancer	1.89e-05	0.000255	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SRC—lung cancer	1.88e-05	0.000255	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTA4—lung cancer	1.88e-05	0.000254	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—RAF1—lung cancer	1.88e-05	0.000254	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SDC4—lung cancer	1.85e-05	0.00025	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGFR1—lung cancer	1.84e-05	0.00025	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	1.84e-05	0.000249	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—lung cancer	1.83e-05	0.000248	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTA2—lung cancer	1.83e-05	0.000248	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOA1—lung cancer	1.83e-05	0.000248	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HIF1A—lung cancer	1.81e-05	0.000246	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MMP1—lung cancer	1.81e-05	0.000245	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—STK11—lung cancer	1.77e-05	0.00024	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTA1—lung cancer	1.77e-05	0.000239	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOA1—lung cancer	1.75e-05	0.000237	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.75e-05	0.000237	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCC3—lung cancer	1.75e-05	0.000237	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KDR—lung cancer	1.73e-05	0.000235	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—MAPK3—lung cancer	1.73e-05	0.000235	CbGpPWpGaD
Valsartan—ALB—Hemostasis—APOA1—lung cancer	1.73e-05	0.000234	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKR1C1—lung cancer	1.69e-05	0.000229	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—RRM1—lung cancer	1.68e-05	0.000228	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA3—lung cancer	1.68e-05	0.000228	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CG—lung cancer	1.67e-05	0.000226	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.67e-05	0.000226	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTP1—lung cancer	1.64e-05	0.000223	CbGpPWpGaD
Valsartan—ALB—Metabolism—UGT1A1—lung cancer	1.64e-05	0.000222	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CG—lung cancer	1.6e-05	0.000217	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KIT—lung cancer	1.6e-05	0.000217	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APC—lung cancer	1.6e-05	0.000217	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—NRAS—lung cancer	1.6e-05	0.000217	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAT—lung cancer	1.6e-05	0.000217	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.59e-05	0.000215	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—POMC—lung cancer	1.59e-05	0.000215	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNG11—lung cancer	1.58e-05	0.000214	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—B4GALT5—lung cancer	1.58e-05	0.000214	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGF—lung cancer	1.58e-05	0.000214	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CG—lung cancer	1.58e-05	0.000214	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOA1—lung cancer	1.57e-05	0.000213	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EGF—lung cancer	1.56e-05	0.000211	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCB1—lung cancer	1.55e-05	0.000211	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CREBBP—lung cancer	1.55e-05	0.00021	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA4—lung cancer	1.54e-05	0.000208	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—MAPK3—lung cancer	1.53e-05	0.000207	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TYMS—lung cancer	1.53e-05	0.000207	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—POMC—lung cancer	1.52e-05	0.000206	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—lung cancer	1.51e-05	0.000204	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALDOA—lung cancer	1.51e-05	0.000204	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	1.5e-05	0.000204	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BRAF—lung cancer	1.5e-05	0.000204	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA2—lung cancer	1.5e-05	0.000203	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—APOA1—lung cancer	1.5e-05	0.000203	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6R—lung cancer	1.48e-05	0.000201	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CREBBP—lung cancer	1.48e-05	0.000201	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CD—lung cancer	1.47e-05	0.000199	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CREBBP—lung cancer	1.46e-05	0.000198	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOA3—lung cancer	1.46e-05	0.000198	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—lung cancer	1.46e-05	0.000197	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—lung cancer	1.45e-05	0.000196	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA1—lung cancer	1.45e-05	0.000196	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.44e-05	0.000195	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—lung cancer	1.43e-05	0.000194	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1A1—lung cancer	1.43e-05	0.000194	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCC3—lung cancer	1.43e-05	0.000194	CbGpPWpGaD
Valsartan—ALB—Metabolism—ADCY1—lung cancer	1.42e-05	0.000193	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCG2—lung cancer	1.42e-05	0.000193	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ERCC2—lung cancer	1.42e-05	0.000192	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAP2K1—lung cancer	1.41e-05	0.000192	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CD—lung cancer	1.41e-05	0.00019	CbGpPWpGaD
Valsartan—ALB—Metabolism—ENO2—lung cancer	1.4e-05	0.000189	CbGpPWpGaD
Valsartan—ALB—Metabolism—HPGDS—lung cancer	1.4e-05	0.000189	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—lung cancer	1.39e-05	0.000189	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CD—lung cancer	1.39e-05	0.000188	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPP2R1B—lung cancer	1.39e-05	0.000188	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKR1C1—lung cancer	1.38e-05	0.000188	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—KRAS—lung cancer	1.38e-05	0.000186	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.37e-05	0.000185	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTT1—lung cancer	1.35e-05	0.000183	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—UGT1A1—lung cancer	1.34e-05	0.000182	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2A6—lung cancer	1.34e-05	0.000181	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCLC—lung cancer	1.34e-05	0.000181	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.33e-05	0.000181	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNG11—lung cancer	1.3e-05	0.000176	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—lung cancer	1.29e-05	0.000175	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CB—lung cancer	1.28e-05	0.000173	CbGpPWpGaD
Valsartan—ALB—Metabolism—ENO1—lung cancer	1.27e-05	0.000172	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—CREBBP—lung cancer	1.27e-05	0.000172	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—lung cancer	1.27e-05	0.000172	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.26e-05	0.000171	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—lung cancer	1.26e-05	0.000171	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MDM2—lung cancer	1.26e-05	0.000171	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RAF1—lung cancer	1.25e-05	0.00017	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ERBB2—lung cancer	1.24e-05	0.000168	CbGpPWpGaD
Valsartan—ALB—Hemostasis—RAF1—lung cancer	1.24e-05	0.000168	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALDOA—lung cancer	1.23e-05	0.000167	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOA1—lung cancer	1.23e-05	0.000166	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MTOR—lung cancer	1.22e-05	0.000166	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CB—lung cancer	1.22e-05	0.000166	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CB—lung cancer	1.21e-05	0.000164	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOA3—lung cancer	1.2e-05	0.000162	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—lung cancer	1.18e-05	0.000159	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.18e-05	0.000159	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.18e-05	0.000159	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—HRAS—lung cancer	1.17e-05	0.000158	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—lung cancer	1.17e-05	0.000158	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADCY1—lung cancer	1.16e-05	0.000158	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCG2—lung cancer	1.16e-05	0.000158	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HPGDS—lung cancer	1.14e-05	0.000155	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ENO2—lung cancer	1.14e-05	0.000155	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2E1—lung cancer	1.14e-05	0.000154	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—lung cancer	1.14e-05	0.000154	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPP2R1B—lung cancer	1.14e-05	0.000154	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—lung cancer	1.13e-05	0.000153	CbGpPWpGaD
Valsartan—ALB—Metabolism—NQO1—lung cancer	1.12e-05	0.000152	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—lung cancer	1.12e-05	0.000152	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CG—lung cancer	1.12e-05	0.000152	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.12e-05	0.000152	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—lung cancer	1.12e-05	0.000152	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—lung cancer	1.11e-05	0.000151	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTT1—lung cancer	1.11e-05	0.00015	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTEN—lung cancer	1.1e-05	0.00015	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.1e-05	0.000149	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—lung cancer	1.1e-05	0.000149	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCLC—lung cancer	1.1e-05	0.000148	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2A6—lung cancer	1.1e-05	0.000148	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JUN—lung cancer	1.09e-05	0.000148	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.09e-05	0.000148	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.09e-05	0.000148	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—RAF1—lung cancer	1.07e-05	0.000145	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—POMC—lung cancer	1.07e-05	0.000145	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—lung cancer	1.06e-05	0.000144	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1A—lung cancer	1.06e-05	0.000144	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTEN—lung cancer	1.06e-05	0.000143	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—EP300—lung cancer	1.05e-05	0.000143	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CREBBP—lung cancer	1.04e-05	0.000141	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ENO1—lung cancer	1.04e-05	0.000141	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.03e-05	0.00014	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—lung cancer	1.03e-05	0.00014	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.02e-05	0.000138	CbGpPWpGaD
Valsartan—ALB—Metabolism—STK11—lung cancer	1.01e-05	0.000137	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EP300—lung cancer	1.01e-05	0.000137	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EP300—lung cancer	9.97e-06	0.000135	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CD—lung cancer	9.85e-06	0.000133	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SRC—lung cancer	9.81e-06	0.000133	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—lung cancer	9.72e-06	0.000132	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SRC—lung cancer	9.7e-06	0.000131	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—lung cancer	9.56e-06	0.00013	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTEN—lung cancer	9.52e-06	0.000129	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—lung cancer	9.46e-06	0.000128	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—lung cancer	9.44e-06	0.000128	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NRAS—lung cancer	9.44e-06	0.000128	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTP1—lung cancer	9.38e-06	0.000127	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NRAS—lung cancer	9.33e-06	0.000126	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2E1—lung cancer	9.31e-06	0.000126	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NQO1—lung cancer	9.21e-06	0.000125	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAT—lung cancer	9.13e-06	0.000124	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—EP300—lung cancer	9.08e-06	0.000123	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK3—lung cancer	9.04e-06	0.000123	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	9.02e-06	0.000122	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	8.93e-06	0.000121	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK3—lung cancer	8.93e-06	0.000121	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCB1—lung cancer	8.88e-06	0.00012	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—lung cancer	8.79e-06	0.000119	CbGpPWpGaD
Valsartan—ALB—Metabolism—TYMS—lung cancer	8.72e-06	0.000118	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—lung cancer	8.62e-06	0.000117	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—lung cancer	8.6e-06	0.000117	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CB—lung cancer	8.59e-06	0.000116	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—lung cancer	8.51e-06	0.000115	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—STK11—lung cancer	8.3e-06	0.000112	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1A1—lung cancer	8.17e-06	0.000111	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KRAS—lung cancer	8.13e-06	0.00011	CbGpPWpGaD
Valsartan—ALB—Metabolism—ERCC2—lung cancer	8.11e-06	0.00011	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KRAS—lung cancer	8.03e-06	0.000109	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	7.79e-06	0.000106	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—lung cancer	7.79e-06	0.000106	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTP1—lung cancer	7.68e-06	0.000104	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAT—lung cancer	7.47e-06	0.000101	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—lung cancer	7.47e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	7.43e-06	0.000101	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTEN—lung cancer	7.42e-06	0.000101	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—lung cancer	7.38e-06	9.99e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCB1—lung cancer	7.27e-06	9.85e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—lung cancer	7.22e-06	9.79e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TYMS—lung cancer	7.14e-06	9.67e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—lung cancer	7.14e-06	9.67e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—EP300—lung cancer	7.08e-06	9.59e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—lung cancer	7.06e-06	9.56e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA1—lung cancer	7.01e-06	9.5e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HRAS—lung cancer	6.91e-06	9.36e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HRAS—lung cancer	6.82e-06	9.25e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	6.72e-06	9.1e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1A1—lung cancer	6.69e-06	9.07e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ERCC2—lung cancer	6.64e-06	8.99e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—lung cancer	6.61e-06	8.96e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CG—lung cancer	6.4e-06	8.67e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—lung cancer	6.36e-06	8.62e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—lung cancer	6.1e-06	8.26e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—POMC—lung cancer	6.09e-06	8.26e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—lung cancer	6.03e-06	8.16e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CREBBP—lung cancer	5.94e-06	8.04e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA1—lung cancer	5.74e-06	7.78e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CD—lung cancer	5.63e-06	7.63e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.5e-06	7.45e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CG—lung cancer	5.24e-06	7.1e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—lung cancer	5.23e-06	7.09e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—POMC—lung cancer	4.99e-06	6.76e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CB—lung cancer	4.91e-06	6.65e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—lung cancer	4.86e-06	6.59e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CREBBP—lung cancer	4.86e-06	6.58e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CD—lung cancer	4.61e-06	6.24e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—lung cancer	4.55e-06	6.16e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—lung cancer	4.28e-06	5.79e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTEN—lung cancer	4.24e-06	5.74e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—EP300—lung cancer	4.04e-06	5.48e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CB—lung cancer	4.02e-06	5.44e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—lung cancer	3.98e-06	5.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTEN—lung cancer	3.47e-06	4.7e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—EP300—lung cancer	3.31e-06	4.48e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—lung cancer	2.99e-06	4.05e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—lung cancer	2.45e-06	3.32e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—lung cancer	2.44e-06	3.31e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—lung cancer	2e-06	2.71e-05	CbGpPWpGaD
